派格生物医药-B(02565)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

02565 派格生物医药-B

休市中 09-11 16:08:55

5.810

+0.190

+3.38%

最高5.825	最低5.475	成交量989.71万
今开5.620	昨收5.620	日振幅6.23%
总市值22.72亿	流通市值22.43亿	总股本3.91亿
成交额5,636万	换手率2.56%	流通股本3.86亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

免责声明:香港交易所资讯服务有限公司、其控股公司及／或该等控股公司的任何附属公司均竭力确保所提供信息的准确和可靠度，但不能保证其绝对准确和可靠，且亦不会承担因任何不准确或遗漏而引起的任何损失或损害的责任（不管是否侵权法下的责任或合约责任又或其它责任）

{"stockData":{"symbol":"02565","market":"HK","secType":"STK","nameCN":"派格生物医药-B","latestPrice":5.81,"timestamp":1789114135007,"preClose":5.62,"halted":0,"volume":9897050,"delay":0,"changeRate":0.033807829181494574,"floatShares":386000000,"shares":391000000,"eps":-0.6429952315969444,"marketStatus":"休市中","change":0.19,"latestTime":"09-11 16:08:55","open":5.62,"high":5.825,"low":5.475,"amount":56355607,"amplitude":0.062278,"askPrice":5.815,"askSize":56450,"bidPrice":5.81,"bidSize":45350,"shortable":3,"etf":0,"ttmEps":-0.9979192467805436,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1789349400000},"marketStatusCode":7,"adr":0,"listingDate":1748275200000,"exchange":"SEHK","adjPreClose":5.62,"openAndCloseTimeList":[[1789090200000,1789099200000],[1789102800000,1789113600000]],"volumeRatio":1.677904,"lotSize":50,"spreadScale":0,"tradeCurrency":"HKD"},"requestUrl":"/m/hq/s/02565","defaultTab":"news","newsList":[{"id":"1161944042","title":"派格生物医药-B 8月股份变动月报表：股本维持稳定","url":"https://stock-news.laohu8.com/highlight/detail?id=1161944042","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1161944042?lang=zh_cn&edition=full","pubTime":"2026-09-03 18:02","pubTimestamp":1788429724,"startTime":"0","endTime":"0","summary":"派格生物医药(杭州)股份有限公司于2026年9月3日披露了截至2026年8月31日的股份变动月报表，报告期内公司股本结构保持总体稳定。\n根据月报信息，派格生物医药-B在本报告期内普通股H股已发行数量为386,002,390股，非上市股份为5,089,142股，名义每股面值为人民币1元。两类股份数量与上月相比无增加或减少。公司已确认在指定月度内无新增发行、回购、注销或库藏股相关活动，公司总注册股本仍为人民币391,091,532元。\n月报还显示，公司目前已满足适用的公众持股量要求。公告最后由联席公司秘书黄一峰签署。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02565"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664840055","title":"港股开盘向好 恒指高开0.68% 信达生物（01801）涨3.73%","url":"https://stock-news.laohu8.com/highlight/detail?id=2664840055","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2664840055?lang=zh_cn&edition=full","pubTime":"2026-09-03 09:26","pubTimestamp":1788398766,"startTime":"0","endTime":"0","summary":"金吾财讯 | 港股开盘向好，恒指高开0.68%，国企指数高开0.75%，恒生科技指数高开0.71%。信达生物涨3.73%，联想集团涨3.33%，老铺黄金涨2.60%，京东健康涨2.43%，农夫山泉涨2.39%，网易涨1.82%。京东健康高开2.43%，公司与立康生命科技签署战略合作协议。外围气氛持续紧张，投资者忧虑债息高企及地缘政局紧张，不过考虑到早前跌势较大，短线大市有机会展现技术反弹，预料指数继续于25,000至26,000点水平上落。","market":"hk","thumbnail":"https://static.szfiu.com/news/20210810/NGVhNjVkZTQ2ODU4ZWQyYjc4YjcyMmRkNWUzMjAzNTczNzI1NTIy.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20210810/NGVhNjVkZTQ2ODU4ZWQyYjc4YjcyMmRkNWUzMjAzNTczNzI1NTIy.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1990504","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1224709979.USD","LU0463099449.HKD","HK0000320223.HKD","LU0287142896.SGD","LU0048580855.USD","LU2242644610.SGD","LU1023057109.AUD","LU1688375341.USD","LU0417516571.SGD","01801","LU2399975544.HKD","LU0348767384.USD","LU0359202008.SGD","LU0310800965.SGD","LU0192582467.USD","LU0588545490.SGD","LU0149534421.HKD","LU0683595622.HKD","SG9999006514.SGD","LU2293587155.HKD","LU1770034418.SGD","NNFSF","LU0871576103.HKD","600690","LU1366334651.USD","SG9999014674.SGD","LU0501845795.SGD","BNGE","BK1515","LU1969619763.USD","IE0032834883.USD","SG9999006597.SGD","LU1048596156.SGD","LU1880383440.USD","06181","LU1655091459.SGD","LU0531971595.HKD","KURE","LU1267930227.SGD","BK1226","BK1610","HSTECH","LU1235295612.USD","LU0441854154.USD","LU1794554557.SGD","01024","IE00BMCWC346.EUR","IE00B19Z5X02.USD","LU0228659784.USD","07300","07200","LU0898667661.SGD","LU0877626530.USD","LU0633140560.USD","LU0370786039.SGD","BK1557","SG9999001846.SGD","03115","KSTmain","LU0149721374.USD","SG9999001051.SGD","BK1608","LU0791590937.USD","BK1570","LU0456846285.SGD","LU0210527791.USD","LU1188198961.HKD","LU0326950275.SGD","BK1180","LU1497733631.SGD","LU0188438112.USD","HK0000306701.USD","03419","LU0049112450.USD","LU0348735423.USD","SG9999001093.SGD","SGXZ86797644.SGD","LU0128522157.USD","BK1214","LU1807302812.USD","601857","80992","LU0293314216.USD","NTES","LU0823413587.USD","LU1282651048.USD","HHImain","LU0607220059.USD","LU2051468812.USD","09633","03037","BK1604","02833","LU0737861699.HKD","00857","LU1226288253.USD","LU0561508036.HKD","BK1193","BK1161","LU0431992006.USD","LU0672654166.SGD","LU0359201885.HKD","LU0405327494.USD","06618","LU1497733557.USD","IE00B29SXG58.USD","LU2328871848.SGD","IE0034224299.USD","LU0211977185.USD","IE0031814852.USD","LU0117841782.USD","BK1227","BK1104","LU0784639295.USD","LU0244354667.USD","LU0572940350.SGD","LU0359201612.USD","LU1251922891.USD","SGXZ90724238.SGD","LU1366334578.USD","BK1574","LU0572944931.SGD","IE0009570106.USD","LU1655091616.SGD","IE00B0JY6N72.USD","LU1813983027.USD","LU0173614495.USD","LU0417516902.SGD","LU0348784397.USD","LU0972618739.USD","IE0008368742.USD","LU2097828474.EUR","LU0588546209.SGD","LU0320764755.SGD","LU0348827113.USD","LU0593848301.USD","BK1531","02382","BK1544","IE00BZ08YT58.USD","00992","LU0314109678.HKD","LU0117844026.USD","LU0865486749.SGD","BK1504","BK1200","LU1481107354.HKD","LU1328277881.USD","BK1575","09999","02565","BK1591","81024","BK1589","LNVGY","LU1048588211.SGD","LU2476274308.USD","BK1095","HK0000165453.HKD","LU0821914370.USD","LU1328615791.USD","LU1046422090.SGD","LU0348783233.USD","06690","LU1769817096.USD","LU0128525689.USD","KWEB","LU0634319403.HKD","LU0543330483.HKD","LU2257852520.SGD","LU0708995583.HKD","LU0831103253.SGD","LU1951186391.HKD","BK1588","07500","LU0650527681.SGD","LU2279701549.SGD","02800","LU0890818403.SGD","DRGN","LU0348766576.USD","IE00B031J352.USD","LU2097828714.EUR","IE0008369823.USD","LU0052750758.USD","LU0594300179.USD","LU1224444064.USD","IE0003895053.USD","TCHI","SGXZ62798434.SGD","LU0611395673.USD","LU0049853897.USD","LU0039217434.USD","LU2778985437.USD","LU0823413660.USD","IE00BPRC5H50.USD","LU1211504680.USD","LU0594300419.USD","IE00BWDBJ730.SGD","LU0320764599.SGD","LU1282651121.HKD","09926","80291","LU1522347837.USD","LU1115378108.SGD","LU1785774172.SGD","LU0329678337.USD","BK1247","LU1226287875.USD","IE0003795394.USD","LU2097828631.EUR","LU2097828557.USD","LU0106959298.USD","LU1981816686.USD","IE00B97KM107.HKD","LU0572939691.SGD","LU0169518387.USD","LU0264606111.USD","LU1634259557.SGD","83115","IE00BYV24P56.USD","HK0000320264.USD","LU1719994722.HKD","LU0140636845.USD","LU0417516738.SGD","LU0405327148.USD","LU0640798160.USD","IE00B031HY20.USD","LU2097828805.USD","SG9999003461.SGD","SG9999004220.SGD","LU0791591158.USD","LU0348783662.USD","LU0029875118.USD","09115","IE0032431581.USD","LU0327786744.USD","IE00BQJZWZ67.USD","LU1226288170.HKD","LU0588545730.USD","BK1571","FDNI","LU0328353924.USD","LU1720050803.USD","BK1170","LU0469268626.HKD","LU0502904849.HKD","SOCL","LU0737861772.HKD","82800","LU0456827905.SGD","LU2476274720.SGD","LU1769817179.HKD","LU1497734951.SGD","LU0605514214.HKD","LU2048586759.USD","LU0540923850.HKD","LU0164880469.USD","LU1831875114.USD","LU0868486357.SGD","LU1634259391.SGD","IE00B0169L03.USD","LU0072462343.USD","BK1607","IE00B543WZ88.USD","LU1226288097.SGD","LU0862451753.SGD","LU2488822045.USD","BK1578","LU0675040207.SGD","MCHmain","LU2152927971.USD","LU0231483743.USD","CRHKY","IE0003851619.USD","LU1226287529.USD","IE00B067MR52.USD","LU0205439572.USD","LU1808992512.USD","LU0164865239.USD","HK0000306685.HKD","LU1303224171.USD","BK1510","LU0828237510.HKD","BK1590","LU0052756011.USD","LU0348825331.USD","BK1615","86618","LU0329678170.USD","LU1119993845.HKD","LU1880383366.USD","LU0181495838.USD","BK1583","LU0210526637.USD","LU1734074674.USD","LU2039709279.SGD","LU0455707207.USD","LU0633140727.USD","LU0051755006.USD","IE00B5MMRT66.SGD","HSI","LU0588545904.SGD","LU1675838814.USD","LU0348805143.USD","LU0307460666.USD","LU0315178854.USD","IE00BZ08YR35.GBP","BK1528","LU1226287792.SGD","BK1521","LU0072913022.USD","LU0862451837.USD","513600","00291","BK1609","BK1526","LU0106252389.USD","BK1142","LU1961090484.USD","IE00BZ08YS42.EUR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664890437","title":"从“走出去”到“被找上门”：派格生物(02565)创新资产的国际吸引力正在形成","url":"https://stock-news.laohu8.com/highlight/detail?id=2664890437","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2664890437?lang=zh_cn&edition=full","pubTime":"2026-09-02 17:30","pubTimestamp":1788341400,"startTime":"0","endTime":"0","summary":"恰恰相反，合作的核心始终是派格自己的创新分子。当越来越多国际技术平台希望把自己的技术应用在派格的分子上时，被验证的不只是某一种递送技术，更是派格自主创新资产本身的吸引力。派格当前正在出现的，正是这样一种从“主动走出去”向“越来越多合作主动找上门”的变化。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1490972.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["02565","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1146219114","title":"派格生物医药-B（02565）携手韩国SN BioScience　推进三款创新多肽长效化研发","url":"https://stock-news.laohu8.com/highlight/detail?id=1146219114","media":"公告速递","labels":["corporation","SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1146219114?lang=zh_cn&edition=full","pubTime":"2026-09-02 17:06","pubTimestamp":1788339964,"startTime":"0","endTime":"0","summary":"2026年9月2日，派格生物医药-B公告称，公司已与韩国生物科技企业SN BioScience, Inc.签署材料转移协议，双方将利用SN BioScience自主开发的丝氨醇核酸长效药物递送平台，对包括APGP6在内的三款由派格生物医药自主研发的代谢疾病创新多肽候选药物展开联合研究。派格生物医药董事会表示，项目将帮助公司系统验证多款下一代多肽资产与SNA平台的技术适配性，进一步拓展产品在长效化、剂型开发及全球开发方面的空间。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02565"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664897051","title":"派格生物医药（02565）与SN BIOSCIENCE开展联合研发合作","url":"https://stock-news.laohu8.com/highlight/detail?id=2664897051","media":"金吾财讯","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2664897051?lang=zh_cn&edition=full","pubTime":"2026-09-02 17:05","pubTimestamp":1788339915,"startTime":"0","endTime":"0","summary":"SN BioScience为一家韩国生物科技公司，专注于肥胖及代谢疾病以及肿瘤领域差异化治疗平台的开发。根据MTA，SN BioScience将其自主开发的丝氨醇核酸长效药物递送平台应用于本集团包括APGP6在内的三款自主研发代谢疾病创新多肽候选药物。","market":"sg","thumbnail":"https://static.szfiu.com/news/20241108/MTU2NzYxOTI1Mjg5.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20241108/MTU2NzYxOTI1Mjg5.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1990483","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0128526141.USD","02565","BK4585","XBI","399441","BK1161","LU2242644610.SGD","BK4581","LU0029874061.USD","SN","161726","BK4588","BK4191"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1160476733","title":"派格生物医药-B携手合作：Sna平台与三款肽候选药物（含APGP6）强强联合","url":"https://stock-news.laohu8.com/highlight/detail?id=1160476733","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1160476733?lang=zh_cn&edition=full","pubTime":"2026-09-02 17:02","pubTimestamp":1788339752,"startTime":"0","endTime":"0","summary":"派格生物医药-B（PEGBIO CO-B）宣布达成一项合作协议，旨在将其专有的Sna平台与公司旗下三款肽候选药物（其中包括APGP6）进行深度融合。\n此次战略合作的核心，在于将Sna平台的技术优势，与派格生物在肽类药物领域的研发积累相结合。三款候选药物中，APGP6作为代表性产品，备受市场关注。\n消息公布后，市场对该合作模式的前景普遍持积极看法，认为这有望为公司的研发管线增添新的动力。然而，具体合作细节及未来临床进展，仍有待进一步披露。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02565","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662078245","title":"派格生物医药-B(02565.HK)发布中期业绩 研发开支1.1亿元","url":"https://stock-news.laohu8.com/highlight/detail?id=2662078245","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2662078245?lang=zh_cn&edition=full","pubTime":"2026-08-25 16:37","pubTimestamp":1787647040,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BK1161","02565"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1102131714","title":"派格生物医药-B（02565）发布2026年中期业绩：净亏损216,196千元 管线商业化及研发投入同步推进","url":"https://stock-news.laohu8.com/highlight/detail?id=1102131714","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1102131714?lang=zh_cn&edition=full","pubTime":"2026-08-25 16:37","pubTimestamp":1787647024,"startTime":"0","endTime":"0","summary":"2026年8月25日，派格生物医药-B披露截至2026年6月30日止六个月未经审计的中期业绩。报告期内，公司未录得产品销售收入；经营亏损214,233千元，期内亏损216,196千元，同比2025年同期的93,672千元增加122,524千元。基本及摊薄每股亏损为人民币0.55元。截至2026年6月30日，公司流动资产457,181千元，其中现金及现金等价物375,621千元；流动负债178,657千元。报告期内经营活动所用净现金为155,041千元，主要用于研发及管理活动。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02565"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1184545548","title":"派格生物医药-B（02565）拟于8月25日召开董事会审议2026年中期业绩","url":"https://stock-news.laohu8.com/highlight/detail?id=1184545548","media":"公告速递","labels":["dataReport","SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1184545548?lang=zh_cn&edition=full","pubTime":"2026-08-13 17:01","pubTimestamp":1786611710,"startTime":"0","endTime":"0","summary":"派格生物医药（杭州）股份有限公司（02565）8月13日公告，公司董事会将于2026年8月25日（星期二）召开会议，主要议程包括：\n1. 审议及批准本集团截至2026年6月30日止六个月的中期业绩及其刊发；  \n2. 处理任何其他事项。\n董事长、执行董事兼总经理Michael Min Xu将在会上主持相关事宜。除其本人外，董事会成员还包括执行董事王小军，非执行董事Xiangjun Zhou、徐宇虹、翟婷、李宏凯，以及独立非执行董事Jiancun Zhang、陈秧秧、廖亦琳。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02565"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1156396796","title":"异动解读｜派格生物医药-B盘中上涨8.82%，派达康商业化持续催化估值修复","url":"https://stock-news.laohu8.com/highlight/detail?id=1156396796","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1156396796?lang=zh_cn&edition=full","pubTime":"2026-08-13 10:54","pubTimestamp":1786589641,"startTime":"0","endTime":"0","summary":"8月13日，派格生物医药-B盘中上涨8.82%，报6.725港元，成交额8605.05万港元。消息面上，公司核心产品派达康近期在全国多家医疗机构及线上渠道开出首批商业化处方，触发第二笔约4900万港元里程碑付款，连同此前已收取的6100万港元，累计已收及触发权益金约1.1亿港元。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02565"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1198617267","title":"派格生物医药-B更新7月股份变动月报表，股本保持不变","url":"https://stock-news.laohu8.com/highlight/detail?id=1198617267","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1198617267?lang=zh_cn&edition=full","pubTime":"2026-08-05 17:13","pubTimestamp":1785921210,"startTime":"0","endTime":"0","summary":"派格生物医药(杭州)股份有限公司于2026年8月5日公告了截至2026年7月31日的股份变动月报表。公告显示，本月公司已发行股份及注册股本均未发生新增发行或减少，股本保持稳定。根据公告，公司主要股本结构包括H股和非上市股份。公司本月底注册股本总额记为人民币391,091,532元，相比上月底并无增减变动。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02565"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1187818353","title":"异动解读｜派格生物医药-B盘中下跌8.64%，报5.39港元","url":"https://stock-news.laohu8.com/highlight/detail?id=1187818353","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1187818353?lang=zh_cn&edition=full","pubTime":"2026-07-30 15:20","pubTimestamp":1785396008,"startTime":"0","endTime":"0","summary":"7月30日，派格生物医药-B盘中下跌8.64%，报5.39港元/股，成交额2731.27万港元。派格生物医药-B所在的生物科技行业中，个股中，信达生物跌1.73%，康方生物跌2.14%，百济神州跌1.31%，科伦博泰生物跌3.78%，三生制药跌1.03%。（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。）","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02565"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1118803082","title":"异动解读｜派格生物医药-B盘中下跌8.36%，报5.81港元","url":"https://stock-news.laohu8.com/highlight/detail?id=1118803082","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1118803082?lang=zh_cn&edition=full","pubTime":"2026-07-28 14:07","pubTimestamp":1785218875,"startTime":"0","endTime":"0","summary":"7月28日，派格生物医药-B盘中下跌8.36%，报5.81港元/股，成交额3469.47万港元。派格生物医药-B所在的生物科技行业中，个股中，维立志博-B跌6.89%，信达生物涨0.11%，百济神州跌2.8%，康诺亚-B跌5.29%，康方生物跌3.4%。（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。）","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02565"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1177397709","title":"异动解读｜派格生物医药-B盘中下跌8.12%，报6.34港元","url":"https://stock-news.laohu8.com/highlight/detail?id=1177397709","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1177397709?lang=zh_cn&edition=full","pubTime":"2026-07-24 14:00","pubTimestamp":1784872801,"startTime":"0","endTime":"0","summary":"7月24日，派格生物医药-B盘中下跌8.12%，报6.34港元/股，成交额4470.26万港元。派格生物医药-B所在的生物科技行业中，个股中，信达生物跌1.48%，百济神州涨2.48%，康方生物跌3.89%，科伦博泰生物跌1.34%，三生制药跌2.16%。（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。）","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02565"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2653775152","title":"首批处方落地即触发4900万港元权益金 派格生物(02565.HK)商业化进入价值兑现期","url":"https://stock-news.laohu8.com/highlight/detail?id=2653775152","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2653775152?lang=zh_cn&edition=full","pubTime":"2026-07-22 18:30","pubTimestamp":1784716234,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["02565","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1152538651","title":"派格生物医药-B(02565)派达康®落地全国首批商业化处方 触发4,900万港元里程碑付款","url":"https://stock-news.laohu8.com/highlight/detail?id=1152538651","media":"公告速递","labels":["productRelease","SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1152538651?lang=zh_cn&edition=full","pubTime":"2026-07-22 18:05","pubTimestamp":1784714748,"startTime":"0","endTime":"0","summary":"2026年7月22日，派格生物医药-B发布自愿性公告称，其自主研发的长效GLP-1受体激动剂维培那肽注射液已在北京大学人民医院、中南大学湘雅二医院等多家医疗机构开出全国首批商业化处方。腾瑞制药已书面确认，将支付约港币4,900万元的第二笔权益金，派格生物医药-B预计在协议约定期限内收取该款项。加上即将到账的4,900万元，派达康在商业化合作层面的里程碑付款持续推进。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02565"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1132079551","title":"异动解读｜派格生物医药-B盘中上涨8.04%，三方战略合作加速派达康商业化放量预期","url":"https://stock-news.laohu8.com/highlight/detail?id=1132079551","media":"行情直击","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1132079551?lang=zh_cn&edition=full","pubTime":"2026-07-21 14:58","pubTimestamp":1784617128,"startTime":"0","endTime":"0","summary":"7月21日，派格生物医药-B盘中上涨8.04%，报7.39港元，成交额1.47亿港元。消息面上，7月17日，派格生物医药-B与上海腾瑞制药及阿里健康在杭州正式签署战略合作协议，三方将整合医药研发、生产及数字化健康服务资源，共同推进核心产品派达康的商业化进程。派达康已获批用于成人2型糖尿病治疗，属独家品种，并已通过国家医保目录调整初步形式审查。市场关注重点已由产品获批转向医院覆盖及线上线下协同带来的放量速度。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02565"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2652235261","title":"港股异动 | 派格生物医药-B(02565)涨超5% 携手三方共同加速打通派达康商业化链路 产品市场放量蓄势待发","url":"https://stock-news.laohu8.com/highlight/detail?id=2652235261","media":"智通财经","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2652235261?lang=zh_cn&edition=full","pubTime":"2026-07-20 11:43","pubTimestamp":1784519009,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，派格生物医药-B涨超5%，截至发稿，涨5.41%，报7.01港元，报1.32亿港元。消息面上，7月17日，派格生物医药-B、上海腾瑞制药股份有限公司与阿里健康在杭州正式签署战略合作协议。下一阶段，市场对派达康的关注重点，将由“产品能否获批”转向医院覆盖、医生处方、患者持续用药以及线上线下协同带来的放量速度。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1469612.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["02565","BK4588","BK4581","VXUS","399441","KCAI","XBI","161726","BK4585","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1196884965","title":"阿里健康宣布与天力士制药、派格生物医药就GLP-1RA药物达成战略合作","url":"https://stock-news.laohu8.com/highlight/detail?id=1196884965","media":"美股速递","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1196884965?lang=zh_cn&edition=full","pubTime":"2026-07-17 19:58","pubTimestamp":1784289496,"startTime":"0","endTime":"0","summary":"阿里健康发布公告称，已与天力士制药及派格生物医药-B正式签署关于GLP-1RA药物的战略合作协议。此举旨在整合各方在医药研发、生产及数字化健康服务领域的优势资源，共同推进该创新药物的开发与商业化进程。GLP-1RA类药物近年来在全球糖尿病及肥胖症治疗市场备受关注，市场潜力巨大。通过此次合作，阿里健康有望进一步强化其医药健康生态布局，而天力士制药与派格生物医药-B则将借助阿里健康的平台与用户基础，加速产品市场渗透。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02565","BK1617","BK1501","BK1591","HK0000165453.HKD","BK1142","BK1615","BK1589","00241","BK1515","BK1584","BK1189","BK1247","BK1610","BK1502","BK1571","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2652404980","title":"派格生物-B(02565)联手腾瑞制药、阿里健康，派达康商业化链路加速打通，市场放量蓄势待发","url":"https://stock-news.laohu8.com/highlight/detail?id=2652404980","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2652404980?lang=zh_cn&edition=full","pubTime":"2026-07-17 18:00","pubTimestamp":1784282400,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，7月17日，派格生物-B、上海腾瑞制药股份有限公司与阿里健康在杭州正式签署战略合作协议。派达康已获批用于成人2型糖尿病治疗。对于派格生物而言，此次与腾瑞制药、阿里健康达成战略合作，不仅进一步完善了派达康的商业化版图，也释放出更加清晰的信号：随着产品差异化、全国推广网络和数字化患者入口逐步汇合，派达康正由商业化准备阶段加速驶入真实市场验证阶段，后续放量已蓄势待发。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1469039.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1574","BK1571","BK1615","BK1142","BK1591","BK1191","00241","BK1610","BK1161","BK1589","02565","BK1189","BK1584","BK1247","BK1515","BK1501","BK1502","HK0000165453.HKD","BK1617","01477"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.pegbio.com","stockEarnings":[{"period":"1week","weight":0.0131},{"period":"1month","weight":-0.0599},{"period":"3month","weight":-0.2095},{"period":"6month","weight":-0.8923},{"period":"1year","weight":-0.8872},{"period":"ytd","weight":-0.9158}],"compareEarnings":[{"period":"1week","weight":-0.033},{"period":"1month","weight":-0.0249},{"period":"3month","weight":0.0035},{"period":"6month","weight":-0.0259},{"period":"1year","weight":-0.0491},{"period":"ytd","weight":-0.0322}],"compareStock":{"symbol":"HSI","name":"恒生指数"},"description":"派格生物医药（杭州）股份有限公司是一家主要从事研究及开发慢性病创新疗法的中国公司。该公司的主要产品PB-119是自主开发、接近商业化阶段的长效胰高血糖素样肽1（GLP-1，一种降低血糖水平的肽类激素）受体激动剂。该公司的候选产品包括PB-718、PB-1902、PB-722、PB-2301和PB-2309。该公司的产品主要用于治疗2型糖尿病（T2DM）、肥胖症、非酒精性脂肪性肝炎（NASH）、阿片类药物引起的便秘（OIC，使用阿片类药物引起的胃肠道疾病）及先天性高胰岛素血症（一种罕见的内分泌疾病，患者持续出现低血糖症）等常见慢病及代谢疾病。","exchange":"SEHK","name":"派格生物医药-B","nameEN":"PEGBIO CO-B"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.44.1","shortVersion":"4.44.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"派格生物医药-B(02565)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供派格生物医药-B(02565)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"派格生物医药-B,02565,派格生物医药-B股票,派格生物医药-B股票老虎,派格生物医药-B股票老虎国际,派格生物医药-B行情,派格生物医药-B股票行情,派格生物医药-B股价,派格生物医药-B股市,派格生物医药-B股票价格,派格生物医药-B股票交易,派格生物医药-B股票购买,派格生物医药-B股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"派格生物医药-B(02565)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供派格生物医药-B(02565)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}